STARTUP PROFILE

Precisis

COUNTRY
Germany
FOUNDED
2013
CATEGORY
Neuromodulation
Developing a minimally invasive neuromodulation system to treat drug-resistant focal epilepsy through targeted brain stimulation.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series C+
MODALITY
Others
FORM FACTOR
Implant
INTERFACE DEPTH
Minimally invasive
INDICATION
Epilepsy
TARGET USER
Patients
REGULATORY STAGE
CE-Marked
Precisis is developing a minimally invasive epilepsy neuromodulation system, positioning itself as a more targeted alternative to broader neurostimulation approaches. Its CE-marked status gives it a stronger clinical foothold than many epilepsy-device startups.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
12
NVIDIA and OpenAI invest in neurotech
13 October – 27 October 2026

PRECISIS partnered with Odin Healthcare to introduce EASEE, its minimally invasive brain stimulation implant for drug-resistant focal epilepsy, in the Gulf states, starting with the UAE.

Articles featuring
Precisis
No items found.